References
Anderson, K.C. (2005). Lenalidomide and thalidomide: Mechanisms of action—Similarities and differences. Seminars in Hematology, 42(4, Suppl. 4), S3--S8.
Bennett, C.L., Hussain, Z., Courtney, M., Yarnold, P., Raisch, D., & McKoy, J.M. (2006). RADAR update on thalidomide (Thal) - and lenalidomide (Len)- associated venous thromboembolism (VTE): Safety concerns persist for multiple myeloma (MM) despite FDA approvals in this setting [Abstract # 3310]. Retrieved February 3, 2007, from
http://meeting.bloodjournal.org/cgi/content/abstract/108/11/3310?maxtoshow=&HITS=10&hits=10&RESULTFORMAT=1&title=lenalidomide&andorexacttitle=and&andorexacttitleabs=and&andorexactfulltext=and&searchid=1&FIRSTINDEX=0&sortspec=relevance&resourcetype=HWCIT
Celgene Corporation. (2006b). Revlimid® (lenalidomide) [Package insert]. Summit, NJ: Author.
Celgene Corporation. (2006d). Thalomid® (thalidomide) [package insert]. Summit, NJ: Author.
Corral, L.G., Haslett, P.A., Muller, G.W., Chen, R., Wong, L.M., Ocampo, C.J., et al. (1999). Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha. Journal of Immunology, 163, 380--386.
Davies, F.E., Raje, N., Hideshima, T., Lentzsch, S., Young, G., Tai, Y.T., et al. (2001). Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma. Blood, 98, 210--216.
Dimopoulos, M.A., Spencer, A., Attal, M., Prince, M., Harousseau, J., Dmoszynska, A., et al. (2005). Study of lenalidomide plus dexamethasone versus dexamethasone alone in relapsed or refractory multiple myeloma (MM): Results of a phase 3 study (MM-010) [Abstract #6]. Blood, 106, 6a.
Doss, D.S. (2006). Advances in oral therapy in the treatment of multiple myeloma. Clinical Journal of Oncology Nursing, 10, 514--520.
Dredge, K., Marriott, J.B., Macdonald, C.D., Man, H.W., Chen, R., Muller, G.W., et al. (2002). Novel thalidomide analogues display anti-angiogenic activity independently of immunomodulatory effects. British Journal of Cancer, 87, 1166--1172.
Gupta, D., Treon, S.P., Shima, Y., Hideshima, T., Podar, K., Tai, Y.T., et al. (2001). Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: Therapeutic applications. Leukemia, 15, 1950--1961.
Hideshima, T., Chauhan, D., Podar, K., Schlossman, R.L., Richardson, P., & Anderson, K.C. (2001). Novel therapies targeting the myeloma cell and its bone marrow microenvironment. Seminars in Oncology, 28, 607--612.
Hideshima, T., Chauhan, D., Shima, Y., Raje, N., Davies, F.E., Tai, Y.T., et al. (2000). Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy. Blood, 96, 2943--2950.
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M.J. (2007). Cancer statistics, 2007. CA: A Cancer Journal for Clinicians, 57(1), 43--66.
Lentzsch, S., Anderson, G., Kurihara, N., Honjo, T., Anderson, J., Mapara, M.Y., et al. (2005). Thalidomide derivative CC-4047 inhibits inhibits osteoclast formation by down regulation of PU.1 [Abstract #629]. Blood, 106, 187a.
Lokhorst, H. (2002). Clinical features and diagnostic criteria. In S. Singhal & J. Mehta (Eds.), Myeloma (pp. 151--168). London: Martin Dunitz Ltd.
Niesvizky, R., Martinez-Banos, D.M., Gelbshtein, U.Y., Cho, H.J., Pearse, R.N., Zafar, F., et al. (2005). Prophylactic low-dose aspirin is effective as antithrombotic therapy in patients receiving combination thalidomide or lenalidomide [Abstract #3454]. Blood, 106, 964a.
Rajkumar, S.V., Hayman, S.R., Lacy, M.Q., Dispenzieri, A., Geyer, S.M., Kabat, B., et al. (2005). Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma. Blood, 106, 4050--4053.
Richardson, P., & Anderson, K. (2004). Immunomodulatory analogs of thalidomide: An emerging new therapy in myeloma. Journal of Clinical Oncology, 22, 3212--3214.
Richardson, P., Jagannath, S., Hussein, M., Berenson, J., Singhal, S., Irwin, D., et al. (2005). A multicenter, single-arm, open-label study to evaluate the efficacy and safety of single-agent lenalidomide in patients with relapsed and refractory multiple myeloma: Preliminary results [Abstract #1565]. Blood, 106, 449a.
Richardson, P.G., Jagannath, S., Schlossman, R., Zeldenrust, S., Rajkumar, S.V., Alsina, M., et al. (2003). A multi-center, randomized, phase II study to evaluate the efficacy and safety of two CDC-5013 dose regimens when used alone or in combination with dexamethasone (dex) for the treatment of relapsed or refractory multiple myeloma (MM) [Abstract #825]. Blood, 100, 235a.
Richardson, P.G., Schlossman, R.L., Weller, E., Hideshima, T., Mitsiades, C., Davies, F., et al. (2002). Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood, 100, 3063--3067.
Singhal, S., Mehta, J., Desikan, R., Ayers, D., Roberson, P., Eddlemon, P., et al. (1999). Antitumor activity of thalidomide in refractory multiple myeloma. New England Journal of Medicine, 341, 1565--1571.
Streetly, M.J., Gyertson, K., Kazmi, M., Zeldis, J., & Schey, S.A. (2007). Prolonged survival with actimid (CC-4047) [Abstract PO-643]. Haematologica, 92(Suppl. 2), 166.
Tariman, J.D. (2003a). Thalidomide: Current therapeutic uses and management of its toxicities. Clinical Journal of Oncology Nursing, 7, 143--147.
Tariman, J.D. (2003b). Understanding novel therapeutic agents for multiple myeloma. Clinical Journal of Oncology Nursing, 7, 521--528.
Weber, D.M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E., et al. (2006). Lenalidomide plus high-dose dexamethasone provides improved overall survival compared to high-dose dexamethasone alone for relapsed or refractory multiple myeloma (MM): Results of a North American phase III study (MM-009) [Abstract # 7521].
Journal of Clinical Oncology, 24(18s). Retrieved February 2, 2007, from
http://www.asco.org/portal/site/ASCO/menuitem.34d60f5624ba07fd506fe310ee37a01d/?vgnextoid=76f8201eb61a7010VgnVCM100000ed730ad1RCRD&vmview=abst_detail_view&confID=40&index=y&abstractID=34363
Zangari, M., Tricot, G., Zeldis, J., Eddlemon, P., Saghafifar, F., & Barlogie, B. (2001). Results of phase 1 study of CC-5013 for the treatment of multiple myeloma (MM) patients who relapse after high dose chemotherapy (HDCT) [Abstract # 3226]. Blood, 98, 775a.
Zeldis, J.B., Williams, B.A., Thomas, S.D., & Elsayed, M.E. (1999). S.T.E.P.S.: A comprehensive program for controlling and monitoring access to thalidomide. Clinical Therapeutics, 21, 319--330.
Zonder, J.A., Durie, B.G.M., McCoy, J., Crowley, J., Zeldis, J.B., Ghannam, L., et al. (2005). High incidence of thrombotic events observed in patients receiving lenalidomide (L) + dexamethasone (D) (LD) as first-line therapy for multiple myeloma (MM) without aspirin (ASA) prophylaxis [Abstract #3455]. Blood, 106, 964a.